617 related articles for article (PubMed ID: 32327719)
1. Complement as a target in COVID-19?
Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
[TBL] [Abstract][Full Text] [Related]
2. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.
Stahel PF; Barnum SR
Front Immunol; 2020; 11():1661. PubMed ID: 32733489
[No Abstract] [Full Text] [Related]
3. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
4. COVID-19: Complement, Coagulation, and Collateral Damage.
Lo MW; Kemper C; Woodruff TM
J Immunol; 2020 Sep; 205(6):1488-1495. PubMed ID: 32699160
[TBL] [Abstract][Full Text] [Related]
5. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
6. Establishing a Unified COVID-19 "Immunome": Integrating Coronavirus Pathogenesis and Host Immunopathology.
Wauters E; Thevissen K; Wouters C; Bosisio FM; De Smet F; Gunst J; Humblet-Baron S; Lambrechts D; Liston A; Matthys P; Neyts J; Proost P; Weynand B; Wauters J; Tejpar S; Garg AD
Front Immunol; 2020; 11():1642. PubMed ID: 32719686
[No Abstract] [Full Text] [Related]
7. Terminal complement inhibition dampens the inflammation during COVID-19.
Kulasekararaj AG; Lazana I; Large J; Posadas K; Eagleton H; Lord Villajin J; Zuckerman M; Gandhi S; Marsh JCW
Br J Haematol; 2020 Aug; 190(3):e141-e143. PubMed ID: 32495372
[No Abstract] [Full Text] [Related]
8. COVID-19, microangiopathy, hemostatic activation, and complement.
Song WC; FitzGerald GA
J Clin Invest; 2020 Aug; 130(8):3950-3953. PubMed ID: 32459663
[No Abstract] [Full Text] [Related]
9. Could severe COVID-19 be considered a complementopathy?
Chatzidionysiou K; Svenungsson E; Faustini F
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32430402
[No Abstract] [Full Text] [Related]
10.
Siddiqui R; Khan NA
ACS Chem Neurosci; 2020 Aug; 11(16):2391-2392. PubMed ID: 32786329
[TBL] [Abstract][Full Text] [Related]
11. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Mastaglio S; Ruggeri A; Risitano AM; Angelillo P; Yancopoulou D; Mastellos DC; Huber-Lang M; Piemontese S; Assanelli A; Garlanda C; Lambris JD; Ciceri F
Clin Immunol; 2020 Jun; 215():108450. PubMed ID: 32360516
[TBL] [Abstract][Full Text] [Related]
12. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
13. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal Stem Cell Therapy Can Transcend Perianal Crohn's Disease: How Colorectal Surgeons Can Help in the Coronavirus Disease 2019 Crisis.
Lightner AL; García-Olmo D
Dis Colon Rectum; 2020 Jul; 63(7):874-878. PubMed ID: 32251143
[No Abstract] [Full Text] [Related]
15. The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019.
Canham MA; Campbell JDM; Mountford JC
J Transl Med; 2020 Sep; 18(1):359. PubMed ID: 32958009
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.
Gladstone DE; Kim BS; Mooney K; Karaba AH; D'Alessio FR
Ann Intern Med; 2020 Nov; 173(10):852-853. PubMed ID: 32628535
[No Abstract] [Full Text] [Related]
17. Audio Interview: Capitalizing on Immune Responses to Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
[No Abstract] [Full Text] [Related]
18. COVID-19: disCOVering the role of complement system.
Conigliaro P; Triggianese P; Perricone C; Chimenti MS; Perricone R
Clin Exp Rheumatol; 2020; 38(4):587-591. PubMed ID: 32723436
[No Abstract] [Full Text] [Related]
19. A double edged-sword - The Complement System during SARS-CoV-2 infection.
Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L
Life Sci; 2021 May; 272():119245. PubMed ID: 33609539
[TBL] [Abstract][Full Text] [Related]
20. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
[Next] [New Search]
